Table 1.

GNAS and KRAS mutations in pyloric gland adenomas and fundic gland polyps from familial adenomatous polyposis patients.

Patient	Dx	Grade of dysplasia	GNAS mutation	KRAS mutation	Type of sample	Sex	Age
1	PGA1	LGD	failed	failed	Biopsy	F	49
1	PGA2	LGD	R201S	G12V	Biopsy	F	53
1	FGP	ND	WT	WT	U	F	49
1	FGP	LGD	WT	WT	Biopsy	F	53
1	FGP	ND	WT	WT	Biopsy	F	52
1	FGP	ND	WT	WT	U	F	50
2	PGA3	Focal HGD	R201H	G12V	Polypectomy	F	24
2	PGA4	IGD	R201H	G12V	Polypectomy	F	26
2	FGP	ND	WT	WT	Biopsy	F	29
2	FGP	LGD	WT	WT	Biopsy	F	21
3	PGA5	IGD	R201C	WT	Polypectomy	M	61
3	PGA6	LGD	R201C	WT	biopsy	M	66
3	PGA7	LGD	R201C	WT	biopsy	M	65
3	FGP	ND	WT	WT	biopsy	M	66
4	FGP	LGD	WT	WT	biopsy	F	35
4	FGP	LGD	WT	WT	biopsy	F	34
4	FGP	LGD	WT	WT	biopsy	F	34
4	FGP	LGD	WT	WT	biopsy	F	34
4	FGP	LGD	WT	WT	biopsy	F	33
4	FGP	LGD	WT	WT	biopsy	F	33
4	FGP	LGD	WT	WT	biopsy	F	33
5	FGP	LGD	WT	WT	EMR	F	42
5	FGP	LGD	WT	WT	biopsy	F	42
5	FGP	ND	WT	WT	biopsy	F	34
6	FGP	LGD	WT	WT	biopsy	M	26

Dx: diagnosis; PGA: pyloric gland adenoma; FGP: fundic gland adenoma; ND: no dysplasia; LGD: low-grade dysplasia; IGD: intermediate grade dysplasia; HGD: high-grade dysplasia; WT: wilt-type; U: unknown; EMR: Endoscopic mucosal resection